Tandem Diabetes Care Toekomstige groei

Future criteriumcontroles 1/6

Tandem Diabetes Care zal naar verwachting groeien in winst en omzet met respectievelijk 52.2% en 10.7% per jaar. De winst per aandeel zal naar verwachting groeien met 56% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -0.7% zijn.

Belangrijke informatie

52.2%

Groei van de winst

56.0%

Groei van de winst per aandeel

Medical Equipment winstgroei	18.6%
Inkomstengroei	10.7%
Toekomstig rendement op eigen vermogen	-0.7%
Dekking van analisten	Good
Laatst bijgewerkt	22 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

BOVESPA:T2ND34 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,097	-46	30	59	16
12/31/2025	988	-79	-5	27	20
12/31/2024	890	-115	-18	5	20
6/30/2024	796	-136	-64	-20	N/A
3/31/2024	770	-141	-67	-21	N/A
12/31/2023	748	-223	-83	-32	N/A
9/30/2023	771	-208	-49	-19	N/A
6/30/2023	790	-224	-41	5	N/A
3/31/2023	795	-204	-33	18	N/A
12/31/2022	801	-95	8	50	N/A
9/30/2022	791	-68	21	64	N/A
6/30/2022	766	-13	50	74	N/A
3/31/2022	738	6	74	96	N/A
12/31/2021	703	16	88	111	N/A
9/30/2021	661	22	85	107	N/A
6/30/2021	605	7	62	87	N/A
3/31/2021	542	-25	45	74	N/A
12/31/2020	499	-34	-8	25	N/A
9/30/2020	439	-49	-6	29	N/A
6/30/2020	410	-42	5	37	N/A
3/31/2020	394	-17	1	25	N/A
12/31/2019	362	-25	22	42	N/A
9/30/2019	330	-24	23	37	N/A
6/30/2019	282	-55	0	10	N/A
3/31/2019	223	-113	-4	0	N/A
12/31/2018	184	-123	-11	-8	N/A
9/30/2018	148	-138	-38	-34	N/A
6/30/2018	129	-119	-52	-50	N/A
3/31/2018	116	-82	N/A	-58	N/A
12/31/2017	108	-73	N/A	-66	N/A
9/30/2017	96	-76	N/A	-68	N/A
6/30/2017	82	-90	N/A	-67	N/A
3/31/2017	83	-87	N/A	-66	N/A
12/31/2016	84	-83	N/A	-61	N/A
9/30/2016	84	-81	N/A	-58	N/A
6/30/2016	88	-70	N/A	-54	N/A
3/31/2016	81	-72	N/A	-59	N/A
12/31/2015	73	-72	N/A	-59	N/A
9/30/2015	62	-79	N/A	-62	N/A
6/30/2015	59	-79	N/A	-61	N/A
3/31/2015	54	-79	N/A	-60	N/A
12/31/2014	50	-80	N/A	-61	N/A
9/30/2014	42	-85	N/A	-61	N/A
6/30/2014	36	-78	N/A	-58	N/A
3/31/2014	32	-74	N/A	-56	N/A
12/31/2013	29	-63	N/A	-48	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat T2ND34 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat T2ND34 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat T2ND34 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van T2ND34 ( 10.7% per jaar) zal naar verwachting sneller groeien dan de markt BR ( 7.6% per jaar).

Hoge groei-inkomsten: De omzet van T2ND34 ( 10.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat T2ND34 binnen 3 jaar verliesgevend zal zijn.

Tandem Diabetes Care Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022

Recent updates

Tandem Diabetes Care, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

Tandem Diabetes Care, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell 3000E Value Index

Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024

Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024

Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance

Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA .

Tandem Diabetes Care, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Tandem Diabetes Care, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:Connect Mobile App

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) acquired Capillary Biomedical, Inc.

Tandem Diabetes Care, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Tandem Diabetes Care Reports the Appointments of Myoung Cha and Joao Malagueira as Independent Members of Its Board of Directors, as of June 15, 2022

Tandem Diabetes Care, Inc. Appoints Myoung Cha and Joao Malagueira as Independent Members of its Board of Directors

Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022

Tandem Diabetes Care, Inc., Annual General Meeting, May 25, 2022

Tandem Diabetes Care, Inc. to Report Q1, 2022 Results on May 04, 2022

Tandem Diabetes Care, Inc. Appoints David B. Berger as Executive Vice President, Chief Operating Officer and Assistant Secretary

Tandem Diabetes Care, Inc. Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven